PMID- 32150821
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 3
DP  - 2020 Mar 5
TI  - Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In 
      Vivo Targeting.
LID - 10.3390/cancers12030590 [doi]
LID - 590
AB  - Dendritic cells (DCs) have shown great potential as a component or target in the 
      landscape of cancer immunotherapy. Different in vivo and ex vivo strategies of DC 
      vaccine generation with different outcomes have been proposed. Numerous clinical 
      trials have demonstrated their efficacy and safety in cancer patients. However, 
      there is no consensus regarding which DC-based vaccine generation method is 
      preferable. A problem of result comparison between trials in which different 
      DC-loading or -targeting approaches have been applied remains. The employment of 
      different DC generation and maturation methods, antigens and administration 
      routes from trial to trial also limits the objective comparison of DC vaccines. 
      In the present review, we discuss different methods of DC vaccine generation. We 
      conclude that standardized trial designs, treatment settings and outcome 
      assessment criteria will help to determine which DC vaccine generation approach 
      should be applied in certain cancer cases. This will result in a reduction in 
      alternatives in the selection of preferable DC-based vaccine tactics in patient. 
      Moreover, it has become clear that the application of a DC vaccine alone is not 
      sufficient and combination immunotherapy with recent advances, such as immune 
      checkpoint inhibitors, should be employed to achieve a better clinical response 
      and outcome.
FAU - Baldin, Alexey V
AU  - Baldin AV
AUID- ORCID: 0000-0001-6220-5341
AD  - Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 
      119991 Moscow, Russia.
FAU - Savvateeva, Lyudmila V
AU  - Savvateeva LV
AD  - Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 
      119991 Moscow, Russia.
FAU - Bazhin, Alexandr V
AU  - Bazhin AV
AD  - Department of General, Visceral and Transplant Surgery, Ludwig-Maximilians 
      University of Munich, 81377 Munich, Germany.
AD  - German Cancer Consortium (DKTK), Partner Site Munich, 80336 Munich, Germany.
FAU - Zamyatnin, Andrey A Jr
AU  - Zamyatnin AA Jr
AUID- ORCID: 0000-0002-3046-4565
AD  - Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 
      119991 Moscow, Russia.
AD  - Belozersky Institute of Physico-Chemical Biology, Department of Cell Signaling, 
      Lomonosov Moscow State University, 119991 Moscow, Russia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200305
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7139354
OTO - NOTNLM
OT  - anticancer vaccine
OT  - cancer immunotherapy
OT  - combination immunotherapy
OT  - dendritic cell targeting
OT  - dendritic cell vaccine
OT  - dendritic cells
COIS- The authors declare no conflict of interest.
EDAT- 2020/03/11 06:00
MHDA- 2020/03/11 06:01
PMCR- 2020/03/05
CRDT- 2020/03/11 06:00
PHST- 2020/01/31 00:00 [received]
PHST- 2020/02/29 00:00 [revised]
PHST- 2020/03/02 00:00 [accepted]
PHST- 2020/03/11 06:00 [entrez]
PHST- 2020/03/11 06:00 [pubmed]
PHST- 2020/03/11 06:01 [medline]
PHST- 2020/03/05 00:00 [pmc-release]
AID - cancers12030590 [pii]
AID - cancers-12-00590 [pii]
AID - 10.3390/cancers12030590 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 Mar 5;12(3):590. doi: 10.3390/cancers12030590.